PMID- 20445565 OWN - NLM STAT- MEDLINE DCOM- 20101028 LR - 20211020 IS - 1476-5470 (Electronic) IS - 1466-4879 (Print) IS - 1466-4879 (Linking) VI - 11 IP - 5 DP - 2010 Jul TI - The association between the PTPN22 1858C>T variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies. PG - 406-15 LID - 10.1038/gene.2010.12 [doi] AB - The single nucleotide polymorphism 1858C>T in the PTPN22 gene is associated with type 1 diabetes (T1D) in several populations. Earlier reports have suggested that the association may be modified by human leukocyte antigen (HLA), as well as by islet autoantibodies. In a large case-control study of Swedish incident T1D patients and controls, 0-34 years of age, we tested whether the odds ratio (OR) measure of association was dependent on HLA or autoantibodies against the islet autoantigens glutamic acid decarboxylase 65 kDa autoantibodies (GADA), insulin, islet antigen-2, or islet cell. The association between the carrier status of 1858C>T allele in PTPN22 (PTPN22(CT+TT)) and T1D was modified by HLA. In addition, in GADA-positive T1D, the OR was 2.83 (2.00, 3.99), whereas in GADA-negative T1D, the OR was 1.41 (0.98, 2.04) (P for comparison=0.007). The OR of association between PTPN22(CT+TT) and GADA-positive T1D declined with increasing HLA-risk category from 6.12 to 1.54 (P=0.003); no such change was detected in GADA-negative T1D (P=0.722) (P for comparison=0.001). However, the absolute difference in risk between PTPN22(CC) and PTPN22(CT+TT) subjects with high-risk HLA was five times higher than that for subjects with low-risk HLA. We hypothesize that the altered T-cell function because of the PTPN22(1858C>T) polymorphism is exclusively associated with GADA-positive T1D at diagnosis. FAU - Maziarz, M AU - Maziarz M AD - Department of Biostatistics, University of Washington, Seattle, WA 98195-7232, USA. marlenam@u.washington.edu FAU - Janer, M AU - Janer M FAU - Roach, J C AU - Roach JC FAU - Hagopian, W AU - Hagopian W FAU - Palmer, J P AU - Palmer JP FAU - Deutsch, K AU - Deutsch K FAU - Sanjeevi, C B AU - Sanjeevi CB FAU - Kockum, I AU - Kockum I FAU - Breslow, N AU - Breslow N FAU - Lernmark, A AU - Lernmark A CN - Swedish Childhood Diabetes Register CN - Diabetes Incidence in Sweden Study Group LA - eng GR - DK53004/DK/NIDDK NIH HHS/United States GR - R01 DK026190/DK/NIDDK NIH HHS/United States GR - P01 DK053004/DK/NIDDK NIH HHS/United States GR - DK26910/DK/NIDDK NIH HHS/United States GR - 5 P30 DK17047/DK/NIDDK NIH HHS/United States GR - P01 DK053004-04/DK/NIDDK NIH HHS/United States GR - P30 DK017047/DK/NIDDK NIH HHS/United States GR - DK053004/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20100506 PL - England TA - Genes Immun JT - Genes and immunity JID - 100953417 RN - 0 (Autoantibodies) RN - 0 (HLA Antigens) RN - EC 3.1.3.48 (PTPN22 protein, human) RN - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 22) RN - EC 4.1.1.15 (Glutamate Decarboxylase) RN - EC 4.1.1.15 (glutamate decarboxylase 2) SB - IM MH - Adolescent MH - Adult MH - Age Factors MH - Autoantibodies/immunology/*metabolism MH - Case-Control Studies MH - Child MH - Child, Preschool MH - Diabetes Mellitus, Type 1/*genetics MH - Female MH - Genetic Predisposition to Disease/*genetics MH - Genome-Wide Association Study MH - Genotype MH - Glutamate Decarboxylase/*immunology MH - HLA Antigens/*genetics MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - Odds Ratio MH - Polymorphism, Single Nucleotide/*genetics MH - Protein Tyrosine Phosphatase, Non-Receptor Type 22/*genetics MH - Risk Assessment MH - Sweden PMC - PMC3045194 MID - NIHMS268562 EDAT- 2010/05/07 06:00 MHDA- 2010/10/29 06:00 PMCR- 2011/02/25 CRDT- 2010/05/07 06:00 PHST- 2010/05/07 06:00 [entrez] PHST- 2010/05/07 06:00 [pubmed] PHST- 2010/10/29 06:00 [medline] PHST- 2011/02/25 00:00 [pmc-release] AID - gene201012 [pii] AID - 10.1038/gene.2010.12 [doi] PST - ppublish SO - Genes Immun. 2010 Jul;11(5):406-15. doi: 10.1038/gene.2010.12. Epub 2010 May 6.